


Welcome OHDSI: Where's our journey?

Patrick Ryan, PhD
Janssen Research and Development
Columbia University Medical Center
18 October 2017




Odyssey (noun): \oh-d-si\

A long journey full of adventures



πιιμ.//www.merriam-webster.com/αιζιιοπαίγ/odyssey

















































Welcome!

Thank you sponsors



Foundation for Health and Policy



Johnson Johnson OF

OFFICE OF THE CMO



Google Cloud



Deloitte.

ConvergeHEALTH™





BlueCross BlueShield of South Carolina is an independent licensee of the Blue Cross and Blue Shield Association




















OHDSI symposium, by the numbers

- 437 collaborators registered
- 47 participants from 14 different countries
- US collaborators hailing from 29 states
- 48 friends from FDA





OHDSI Symposium, by the numbers

118 different organizations

AbbVie

Bayer

CHOP

Deloitte

Erasmus MC

Fourx

Geisinger

Harvard

IBM

Johns Hopkins

Kaiser Permanente

LTS Consulting

Mayo Clinic

National Institute of Health

Optum

Pfizer

QuintilesIMS

Regenstrief

Sanofi

Tufts

U.S. Bureau of Economic Analysis

Virginia Tech

Weill Cornell Medical College


X

Υ

ZS Associates




OHDSI Symposium, by the numbers





OHDSI Symposium, by the numbers





193

"I'm new to OHDSI and curious to learn more"



OHDSI is an open science community



OHDSI's mission

To improve health, by empowering a community to collaboratively generate the evidence that promotes better health decisions and better care



OHDSI's values

- Innovation: Observational research is a field which will benefit greatly from disruptive thinking. We actively seek and encourage fresh methodological approaches in our work.
- **Reproducibility**: Accurate, reproducible, and well-calibrated evidence is necessary for health improvement.
- **Community**: Everyone is welcome to actively participate in OHDSI, whether you are a patient, a health professional, a researcher, or someone who simply believes in our cause.
- Collaboration: We work collectively to prioritize and address the real world needs of our community's participants.
- **Openness**: We strive to make all our community's proceeds open and publicly accessible, including the methods, tools and the evidence that we generate.
- **Beneficence**: We seek to protect the rights of individuals and organizations within our community at all times.



OHDSI community

We're all in this journey together...





OHDSI' community engagement

- Weekly community web conferences for all collaborators to share their research ideas and progress
- 15 workgroups for solving shared problems of interest
 - Common Data Model, Population-level Estimation, Patient-level
 Prediction, Architecture, Phenotype, NLP, GIS, Oncology, ...
- Active community online discussion: <u>forums.ohdsi.org</u>
- 594 distinct users have made 8,894 posts on 1,631 topics:
 - Implementers, Developers, Researchers, CDM Builders,
 Vocabulary users, OHDSI in Korea, OHDSI in China, OHDSI in Europe



OHDSI is an international data network



Data across the OHDSI community


- 84 organizations have access to 64 different databases
- Patient-level data from various perspectives:
 - Electronic health records, administrative claims, hospital systems, clinical registries, health surveys, biobanks
- Collectively, totaling 1.26 billion patient records
- Data in 17 different countries, with 115 million patient records from outside US

All using one open community data standard: OMOP Common Data Model

Journey of an open community data standard Person Standardized health system data Standardized meta-data Observation period Location Care site CDM source Specimen Provider Concept Death Standardized health Payer plan period Vocabulary Visit_occurrence Standardized clinical data economics Domain Standardized vocabularies Procedure_occurrence Concept class Cost Concept relationship Drug exposure Relationship ⇤ Device_exposure Concept synonym Standardized derived Condition_occurrence Concept ancestor Cohort Measurement ⇤ elements Source to concept map Cohort_attribute Observation ϥ Drug strength Condition era ϥ Note Cohort definition Drug era Note NLP Attribute definition Dose_era Fact relationship




Journey of an open community data standard





OMOP CDM v5.3 ...coming soon!





OHDSI's standardized vocabularies

- 78 Vocabularies across 32 domains
 - MU3 standards: SNOMED, RxNorm, LOINC
 - Disparate sources: ICD9CM, ICD10(CM), Read,
 NDC, Gemscript, CPT4, HCPCS...
- 5,720,848 concepts

Thank you Christian and the Odysseus team for continue to steward, maintain, and improve this invaluable resource for the entire community!

• 32,612,650 concept relationships



OHDSI is collaborating to generate reliable evidence



What is OHDSI's strategy to deliver reliable evidence?

Methodological research

- Develop new approaches to observational data analysis
- Evaluate the performance of new and existing methods
- Establish empirically-based scientific best practices

Open-source analytics development

- Design tools for data transformation and standardization
- Implement statistical methods for large-scale analytics
- Build interactive visualization for evidence exploration

Clinical evidence generation

- Identify clinically-relevant questions that require real-world evidence
- Execute research studies by applying scientific best practices through open-source tools across the OHDSI international data network
- Promote open-science strategies for transparent study design and evidence dissemination



Cohort Method

New-user cohort studies using large-scale regression for propensity and outcome models

Self-Controlled Case Series

Self-Controlled Case Series analysis using few or many predictors, includes splines for age and seasonality.

Self-Controlled Cohort

A self-controlled cohort design, where time preceding exposure is used as control.

IC Temporal Pattern Disc.

A self-controlled design, but using temporal patterns around other exposures and outcomes to correct for timevarying confounding.

Case-control

Case-control studies. matching controls on age, gender, provider, and visit date. Allows nesting of the study in another cohort.

Case-crossover

Case-crossover design including the option to adjust for time-trends in exposures (so-called case-time-control).

Thank you Martijn Schuemie, Marc Suchard, Peter Rijnbeek, and Jenna Reps for leading methods research and development efforts!

exposure-outcome pairs to profile and calibrate a particular analysis design.

reference sets as well as simulations injected in real data to evaluate the performance of methods.

Database Connector

Connect directly to a wide range of database platforms, including SQL Server, Oracle, and PostgreSQL.

Sql Render

Generate SQL on the fly for the various SQL dialects.

Cyclops

Highly efficient implementation of regularized logistic, Poisson and Cox regression.

Ohdsi R Tools

Support tools that didn't fit other categories, including tools for maintaining R libraries.




Journey toward open-source analytics development

- 88 developers on 101 OHDSI GitHub repositories
- Applications released for:
 - CDM ETL design and implementation
 - Clinical characterization (ACHILLES, ATLAS)
 - Population-level effect estimation
 - Patient-level prediction
 - OHDSI network studies (protocol + source code, ARACHNE)



Lates

Journey toward open-source analytics development




Thank you teams from Columbia, Google, Cloudera, Erasmus MC, Odysseus, BlueCrossBlueShield-South Carolina, Regenstrief, Janssen for contributing to the ATLAS 2.2 release!


```
(#436) - Atlas configuration changes - using confg-local.js to override settings in config.js (#450) - Atlas charts upgrade to D3 V4 (#457 & OHDSI/WebAPI#223) - Care_site entropy for report-manager (#447) - Improve client side caching reset (#438) - Refactor service configuration for single WebAPI reference (#464 & OHDSI/WebAPI#224) - Patient Level Prediction specification editor (#463) - Cohort editor - choose collapse strategy exit criteria (#465) - Cohort editor - restrict records with the same visit_occurrence_id
```


Demo at http://ohdsi.org/web/ATLAS



Complementary evidence to inform the patient journey









emerge network ELECTRONIC MEDICAL RECORDS AND GENOMICS











Methodological research

Open-source analytics development

Clinical evidence generation

Observational data management

Clinical characterization

Population-level estimation

Patient-level prediction



Your journey through today

Time	Description
8:30 – 9:30am	YOU ARE HERE
9:30 – 11:30am	Journey Through Clinical Characterization Large-Scale Honest Incidence Speaker: George Hripcsak, MD, MS, Columbia University
	<u>Journey Through Population-Level Estimation</u> Safety Surveillance for the Risk of Angioedema Associated with Levetiracetam Speaker: Jon Duke, MD, MS, Georgia Tech
	Comparative Effectiveness of Alendronate and Raloxifene in Reducing the Risk of Hip Fracture Speakers: Yeesuk Kim, MD, PhD, Hanyang University Marc Suchard, MD, PhD, University of California, Los Angeles
	A Journey Through Patient-Level Prediction Improving Palliative Care Using Patient Level Prediction Speaker: Nigam Shah, MBBS, PhD, Stanford University (webcast)
	Precision Medicine through Patient-Level Prediction of Adverse Events Speaker: Jenna Reps, PhD, Janssen Research & Development



Your journey through today

Time	Description
11:30am-12:30p m	OHDSI Morning Collaborator Showcase – Session 1 Grand Ballroom Foyer Visit the <i>Odd</i> numbered posters and software demonstrations
12:30pm-1:00pm	Buffet Lunch in Grand Ballroom
1:00pm-2:00pm	OHDSI Showcase: Lightning Talks Moderator: Melanie Philofsky, RN, MS, University of Colorado Speakers: Martin Sedlmayr, Friedrich-Alexander-University Erlangen-Nürnberg, Germany Maxim Moinat, The Hyve, Netherlands Nicole Pratt, PhD, University of South Australia Mehr Kashyap, MD Candidate, Stanford University, USA Mary Regina Boland, MA, MPhil, PhD, University of Pennsylvania, USA Rohit Vashisht, PhD, Stanford University, USA Seng Chan You, PhD Candidate, Ajou University, South Korea
2:00pm-3:00pm	OHDSI Morning Collaborator Showcase – Session 2 Grand Ballroom Foyer Visit the <i>even</i> numbered posters and software demonstrations



Vote for the best OHDSI collaborator contributions!





This vote is much too important to allow for undue Russian influence

Your vote counts!!!
Winners will be announced during OHDSI community reaction panel



Your journey through today

Time	Description	
3:00-3:45pm	OHDSI Community Reactions A fun and interactive session to elicit thoughts and future directions from the entire OHDSI community, charge up those smartphones! Jon Duke, MD, Georgia Tech Clair Blacketer, MPH, PMP, Janssen Research & Development Peter Rijnbeek, PhD, Erasmus University Medical Center Andrew Williams, PhD, Maine Medical Center Research Institute Marc Suchard, MD, PhD, University of California, Los Angeles Frank DeFalco, Epidemiology Analytics, Janssen Research & Development	
3:45-4:15pm	Break	
4:15-5:15pm	Panel Discussion: Stakeholder Perspectives On The Journey Ahead Moderator: Kristin Feeney, MPH, ConvergeHEALTH by Deloitte Panelists: Karthik Natarajan, PhD, Columbia University Nasser Al-Qahtani, MSc, MBA, PhD, Saudi Food & Drug Authority Gowtham Rao, MD, PhD, Blue Cross Blue Shield of South Carolina Ming Jack Po, MD, PhD, Google Medical Brain and Google Cloud	
5:15-6:00pm	A surprise journey to end the day!	
6:00-7:30pm	Networking reception	



A journey through the rest of the symposium

Thursday, October 19	9:00am – 5:00pm
	OMOP Common Data Model and Standardized Vocabularies
	Population-Level Estimation

Friday, October 20	9:00am – 5:00pm
	Patient-level prediction
	OHDSI Development Architecture

Thank you tutorial faculty

OMOP Common Data Model and Standardized Vocabularies:

George Hripcsak, Christian Reich, Erica Voss, Karthik Natarajan, Mui Van Zandt, Rimma Belenkaya, Clair Blacketer, Don O'Hara, Don Torok



















Population-Level Estimation: Martijn Schuemie, Marc Suchard, Christophe Lambert



Peter Rijnbeek, Jenna Reps, Joel Swerdel

























Thank you the community!

We're all in this journey together...

